EN DE

Dr. Wu Skincare Co (6523) Fair Value & Analysis

Consumer Defensive · TW · Market cap 4.0B TWD

DW Dr. Wu Skincare Co 6523 · TWO
Price90.80 TWD
Fair Value136.47 TWD
Upside+50.3%
Quality85/100
Watch Dr. Wu Skincare Co for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Highly profitable · 25.5% net margin
generates free cash flow
8.96% dividend yield
Ranks above peers (9/13)
Wide moat 84/100
Evidence: High Range 87.83 TWD – 167.98 TWD Share as image

Fair value as of: Jul 21, 2026

From 25 valuation models · updated 20 days ago

Share price −0.2% over the past month.

A strong business, screening 50% undervalued on our models.

What matters now

  • The rarer combination: high quality (85/100) AND below fair value. That earns a closer look rather than a quick verdict.
  • A fairly wide model range (87.83 TWD to 167.98 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

160.00 TWD 41.56 TWD Fair Value 136.47 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 41.56 TWD – 160.00 TWD · fair‑value band 87.83 TWD – 167.98 TWD · the 90.80 TWD price screens below the 136.47 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Dr. Wu Skincare Co (6523) currently trades at 90.80 TWD, while our model-based Fair Value estimate is 136.47 TWD, implying the stock looks roughly 50.3% undervalued today. The Quality Score stands at 85/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Dr. Wu Skincare Co generated revenue of 1.1B TWD at a net margin of 25.5%. Revenue declined 20.4% year over year. It earns a return on equity of 19.5%. The balance sheet holds a net cash position of 470M TWD. Fundamentals as of Jul 21, 2026

Our scenario range runs from 87.83 TWD (bear case) to 167.98 TWD (bull case); at 90.80 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at 50%, 6523 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 44.49 TWD 53.30 TWD 138.75 TWD 76
Growth DCF 86.07 TWD 117.89 TWD 160.25 TWD 72
Gordon GGM 87.83 TWD 172.27 TWD 265.00 TWD 70
All 25 models by family
DCF Models
FCF DCF 84.44 TWD 119.56 TWD 168.82 TWD 38
Owner Earnings 88.81 TWD 125.93 TWD 177.98 TWD 31
5Y Revenue Exit 52.03 TWD 67.95 TWD 86.92 TWD 39
5Y EBITDA Exit 88.19 TWD 133.49 TWD 184.70 TWD 41
5Y P/E Exit 103.65 TWD 161.51 TWD 220.30 TWD 38
10Y Revenue Exit 62.97 TWD 79.65 TWD 99.54 TWD 36
10Y EBITDA Exit 86.00 TWD 123.39 TWD 170.40 TWD 37
10Y P/E Exit 95.51 TWD 142.08 TWD 196.19 TWD 35
Earnings-Based
Graham-Dodd 52.87 TWD 139.28 TWD 181.89 TWD 54
PEG = 1.0 26.72 TWD 38.18 TWD 49.63 TWD 46
EPV 73.05 TWD 83.44 TWD 92.40 TWD 59
Dividend Discount
Gordon GGM 87.83 TWD 172.27 TWD 265.00 TWD 70
DDM Multi-Stage 87.83 TWD 133.29 TWD 180.00 TWD 61
Multiples
P/E Multiple 122.47 TWD 163.29 TWD 204.11 TWD 63
P/S Multiple 31.12 TWD 41.49 TWD 51.87 TWD 58
P/B Multiple 99.14 TWD 132.19 TWD 165.23 TWD 55
EV/EBIT 128.13 TWD 168.42 TWD 208.71 TWD 53
EV/EBITDA 101.77 TWD 133.28 TWD 164.79 TWD 54
EV/Revenue 34.47 TWD 46.15 TWD 57.82 TWD 43
Asset-Based
NCAV (Graham) 15.04 TWD 20.15 TWD 30.08 TWD 50
Growth DCF
Growth DCF 86.07 TWD 117.89 TWD 160.25 TWD 72
Rev-Margin DCF 52.03 TWD 69.19 TWD 88.57 TWD 67
Economic Profit
Residual Income 44.49 TWD 53.30 TWD 138.75 TWD 76
ROIC Compounder 76.06 TWD 90.73 TWD 106.07 TWD 67
Growth Earnings
Growth-Adj P/E 95.89 TWD 136.98 TWD 178.07 TWD 68

Widest divergence: Growth Earnings (136.98 TWD) versus Asset-Based (20.15 TWD). Highest evidence: Residual Income (76).

Notify me when 6523 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.1B TWD
Revenue growth (YoY) -20.4%
Net margin 25.5%
Return on equity 19.5%
Free cash flow 335M TWD FY2025
P/E ratio 11.6
More key figures
Operating margin 32.0%
EPS (TTM) 7.75 TWD
Dividend yield 9.0%
EPS growth (YoY) -45.2%
Net cash 470M TWD FY2023

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 85/100

Of which business quality 81 · Market factors (momentum, volatility) 41

Profitability 86
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 82
Earnings quality: real cash, not paper profit
Fin. Strength 94
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 99
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Dr. Wu Skincare Co., Ltd. engages in the research, development, production, wholesale, and retail of cosmetics and skincare products in Taiwan and internationally. The company offers makeup removers/cleansers, toners, serums, lotions/creams/gels, masks, UV/DD creams, and eye care products, as well as key repair and body care products.

Full company description

Dr. Wu Skincare Co., Ltd. engages in the research, development, production, wholesale, and retail of cosmetics and skincare products in Taiwan and internationally. The company offers makeup removers/cleansers, toners, serums, lotions/creams/gels, masks, UV/DD creams, and eye care products, as well as key repair and body care products. It also provides health products/beverages. The company also provides products for sensitive skin, dry skin, acne and pores, blackheads, dull and spotty skin, and signs of aging. Dr. Wu Skincare Co., Ltd. was incorporated in 2003 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Dr. Wu Skincare Co reported revenue of 1.2B TWD in FY2025 versus 1.1B TWD in FY2021, a compound +1.4%/yr. Reported net income was 350M TWD in FY2025, compounding +4.3%/yr from FY2021.

Growth Quality 82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.2B TWD
Latest YoY
−5.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.0%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.8%
Avg. growth/yr (12Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.2%
Revenue +1.4%/yr
FY21 1.1B TWD
FY22 927M TWD
FY23 1.1B TWD
FY24 1.2B TWD
FY25 1.2B TWD
Net income +4.3%/yr
FY21 296M TWD
FY22 340M TWD
FY23 425M TWD
FY24 476M TWD
FY25 350M TWD
Character of growth · EPS growth decomposed (2013-2023) +3.7 % p.a.
Revenue per share +4.2 pp

of which total revenue +6.6 pp · buybacks/dilution −2.4 pp

EBIT margin +0.7 pp
Tax rate −0.3 pp
Residual (interest, one-offs) −0.9 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 6523: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Dr. Wu Skincare Co Fair Value". https://www.fairvalue-calculator.com/stock/6523

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 85 · Top 25%
Fair Value upside +50% · Top 25%
Return on equity (TTM) 20% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 26% · Top 25%
Operating margin (TTM) 32% · Top 25%
Revenue growth -20% · Bottom 25%
Dividend yield (TTM) 9.0% · Top 25%

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/E (TTM) 11.6× · Cheaper than 75% of peers
P/B 2.99× · Pricier than 75% of peers
P/S (TTM) 3.69× · Pricier than 75% of peers
P/FCF 0.4× · Cheaper than median
EV/EBITDA 10.7× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 28
FUTURE 0 · sector 4
PAST 78 · sector 26
HEALTH 0 · sector 98
DIVIDEND 100 · sector 50

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
The Procter & Gamble Company PG $146.80 $108.16 -26%
Unilever PLC ULN 1,080 MXN 1,273 MXN +18%
Hindustan Unilever Limited HINDUNILVR ₹2,144 ₹1,000 -53%
Essity AB ESSITYA kr 279.00 kr 250.02 -10%
Godrej Consumer Products Limited GODREJCP ₹1,088 ₹367.64 -66%
Marico Limited MARICO ₹846.75 ₹233.05 -72%
APR Co 278470 375,000 KRW 151,222 KRW -60%
Dabur India Limited DABUR ₹429.45 ₹181.60 -58%
Kimberly-Clark de México, S. A. B. de C. V., KIMBERA 38.07 MXN 50.09 MXN +32%
PT Unilever Indonesia Tbk UNVR 1,730 IDR 1,934 IDR +12%

Compare Dr. Wu Skincare Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Dr. Wu Skincare Co (6523) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 136.47 TWD versus a price of 90.80 TWD, about +50% (undervalued).
What is the fair value of 6523?
Our model-based fair value for Dr. Wu Skincare Co is 136.47 TWD (as of Jul 21, 2026), built from audited fundamentals. The current price is 90.80 TWD.
What is the quality score of 6523?
Dr. Wu Skincare Co has a Quality Score of 85/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Dr. Wu Skincare Co (6523)?
Dr. Wu Skincare Co reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 6523?
The net profit margin of Dr. Wu Skincare Co is about 25.5%, meaning it keeps roughly 25.5% of revenue as net income. Based on the latest reported figures.
Does Dr. Wu Skincare Co pay a dividend?
Dr. Wu Skincare Co currently shows a dividend yield of about 6.11% relative to its recent price (as of Jul 21, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Dr. Wu Skincare Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.